Bioscience engineers from KU Leuven in Belgium have developed a new antibacterial strategy that weakens bacteria by preventing them from cooperating. Unlike with antibiotics, there is no resistance to this strategy, because the non-resistant bacteria outnumber resistant ones. The findings are published in Nature Communications .
Traditional antibiotics kill or reduce the activity of individual bacteria. Some bacteria become resistant to these antibiotics, allowing them to grow further and take over from non-resistant ones. The use of antibiotics therefore causes more and more bacteria to become resistant to antibiotics.
Bacteria, however, also exhibit group behaviour: for example, they can make a protective slime layer or biofilm that envelops their entire bacterial community. Dental plaque is an example of such a biofilm. Biofilms are often the source of bacterial infections. The social behaviour of bacteria is an interesting new target for antibacterial therapy. Stronger together, weaker alone
The researchers showed that blocking slime production of salmonella bacteria weakens the bacterial community, making it easier to remove. They used a chemical, antibacterial substance that was previously developed at KU Leuven. "Without their protective slime layer, the bacteria can be washed away by mechanical forces and killed more easily by antibiotics, disinfectants or the immune system," says Professor Steenackers of the MICA Lab, lead author of the study.
The scientists then compared the development of bacterial resistance to the new substance with that of classical antibiotics in a so-called evolution experiment. Evolution experiments are used to see how microorganisms adapt to a certain situation. "We saw that the bacteria, as a group, did not become resistant to our antibacterial substance, while this did happen with antibiotics, and quickly so," Steenackers explains. "Moreover, we showed those bacteria that were resistant to the new antibacterial substance became outnumbered by non-resistant ones. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology